|
Volumn 4, Issue 3, 2006, Pages 217-218
|
Review
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AUTOANTIBODY;
GLUCOCORTICOID;
RITUXIMAB;
VON WILLEBRAND FACTOR CLEAVING PROTEINASE;
AUTOIMMUNITY;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MECHANISM;
ENZYME ANALYSIS;
ENZYME DEFICIENCY;
ENZYME INHIBITION;
HUMAN;
MEDICAL DECISION MAKING;
MORBIDITY;
MORTALITY;
NOTE;
PATIENT REFERRAL;
PATIENT SELECTION;
PLASMAPHERESIS;
RELAPSE;
REMISSION;
RISK BENEFIT ANALYSIS;
THROMBOTIC THROMBOCYTOPENIC PURPURA;
TREATMENT OUTCOME;
|
EID: 33745454558
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
Times cited : (2)
|
References (5)
|